#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Idarucizumab: a single centre experience


Authors: J. Sokol 1;  I. Plameňová 1;  Ľ. Váleková 1;  F. Nehaj 2;  M. Mokáň ml. 2;  J. Chudej 1;  J. Staško 1
Authors‘ workplace: Klinika hematológie a transfuziológie, Národné centrum hemostázy a trombózy Jesseniova lekárska fakulta v Martine, Univerzita Komenského v Bratislave, Martin, Slovenská republika 1;  I. interná klinika, Jesseniova lekárska fakulta v Martine, Univerzita Komenského v Bratislave Martin, Slovenská republika 2
Published in: Transfuze Hematol. dnes,23, 2017, No. 3, p. 151-157.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

New direct oral anticoagulants (DOACs) are widely used in the primary and secondary prevention of embolic stroke in patients with atrial fibrillation and risk factors according to the CHA2DS2-VASc-Score. Idarucizumab is the first available specific reversal agent for dabigatran and actually the first DOAC antidote to date. In this article, we present two patients with atrial fibrillation on dabigatran, whereby bot required rapid reversal of its effect.

KEY WORDS:
anticoagulants – antidote – atrial fibrillation – idarucizumab


Sources

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: Heart disease and stroke statistics – 2010 update. A report from the American Heart Association. Circulation 2010;121:948–954.

2. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004;110:1042–1046.

3. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics – 2011 update: A report from the American Heart Association. Circulation 2011;123(4):e18–e209.

4. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119–125.

5. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864–2870.

6. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010;41:2731–2738.

7. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e531S–575S.

8. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:1916–1926.

9. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011;123:1144–1150.

10. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation – developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385–1413.

11. Furie KL, Goldstein LB, Albers GW, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: A science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012;43:3442–3453.

12. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 005;45:555–563.

13. Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292–303.

14. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharma-cokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47–59.

15. Remková A, Hulíková M, Kubisz P, et al. Laboratórne monitorovanie liečby novými perorálnymi antikoagulanciami – spoločné odporúčanie odborných spoločností. Vaskulárna medicína 2013;5(S4):3–7.

16. Eriksson BI, Dahl OE, Rosencher N, et al. RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non- nferiority trial. Lancet 2007;370(9591):949–956.

17. Eriksson BI, Dahl OE, Rosencher N, et al. RE-MODEL Study Group. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178–2185.

18. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24(1):1–9.

19. Schulman S, Kearon C, Kakkar AK, et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361(24): 2342–2352.

20. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139–1151.

21. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121(18):3554–3562.

22. Millar CM, Lane DA. Blocking direct inhibitor bleeding. Blood 2013;121(18):3543–3544.

23. Grottke O, van Ryn J, Spronk HM, Rossaint R. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/ liver trauma experimental model. Crit Care 2014;18(1):R27.

24. Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015;386(9994):680–690.

25. Glund S, Stangier J, Schmohl M, et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood 2014;124(21):344.

26. Pollack CV Jr, Reilly PA, Bernstein R, et al. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015;114(1):198–205.

Labels
Haematology Internal medicine Clinical oncology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#